Uyen Huynh-Do, Member of the Executive Board at University of Bern, shared a post on LinkedIn about recent paper she and colleagues co-authored:
“Relapsed/refractory multiple meloma (RRMM) patients with dialysis dependent renal impairment face limited therapeutic options due to exclusion from clinical trials, a lack of evidence-based guidelines, and inferior outcomes.
Here we present the case of a patient with ESRD (End stage Renal Disease) whom we treated with a bispecific antibody targeting B-cell maturation antigen BCMA (BCMA). The patient achieved a very good partial remission and the therapy was well-tolerated with manageable adverse events.
By providing real-world evidence for the use of bispecific antibodies in ESRD patients, this review emphasizes the potential for expanding therapeutic options to this vulnerable population.”
Title: Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
Authors: Michèle Hoffmann, Barbara Jeker, Uyen Huynh-Do, Yara Banz, Jeanne Godau, Elisabeth Weber, Ulrike Bacher, Thomas Pabst
Read The Full Article at Hematological Oncology.
More Posts Featuring Multiple Myeloma.